Friday, 15 Feb 2019

You are here

Selective Use of HLA-B*5801 Testing in Gout

The current edition of JAMA Internal Medicine describes an Asian gout patient who presents with an allopurinol hypersensitivity reaction that could have been diagnosed by testing for HLA-B*5801.

The patient was an elderly Asian male with chronic stage 3 kidney disease, gout, and hypertension. He was prescibed allopurinol (300 mg daily) and colchicine, 0.6 mg daily for acute gout attacks and then a month later presented with acute fever of  102.3°F, myalgia, maculopapular rash over the trunk and arms and laboratory evidence of leukopenia, mild eosinophilia and elevated hepatic enzymes (ALT 308 U/L and AST 248 U/L). 

Drug rash with eosinophilia and systemic symptoms (DRESS) was suspected and allopurinol was discontinued; testing was positive for HLA-B*5801.  He had a complicated course requiring more than 2 months in the hospital.

The allopurinol hypersensitivity syndrome is rare (1 in 1000) and manifests with severe cutaneous reactions that may present as DRESS, Stevens-Johnson syndrome, toxic epidermal necrolysis, etc. 

While HLA-B*5801 is found in 6-12% of certain Asian populations, it is very uncommon in whites (<1.0%) and less common in African Americans (3.8). Thus it is not commonly recommended in these patient groups.

HLA-B*5801 is very prevalent in the Han Chinese, Thai, and Korean people.  In this instance, predictive association between this allele and allopurinol hypersensitivity is very high (Hazard Ration ~ 100) suggesting its testing would be appropriate prior to prescribing allopurinol in certain asian populations. Finding HLA-B*5801 positivity is an indication for urate lowering therapy other than allopurinol.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

U.S. Gout Rates Remain Steady, but Substantial

Using data from 5,467 adults in the US in the National Health and Nutrition Examination Survey (NHANES) for the years 2007-2016, researchers found that the prevalence of gout and hyperuricemia has remained at 3.9%, having doubled from the 1960s to the 1990s, corresponding to an estimated 9.2 million adults with gout in 2015-2016.

Febuxostat Gets Reprieve from FDA Advisory Panel

On January 11, 2019 the FDA convened two advisory panels (the Arthritis Advisory Committee [AAC] and the Drug Safety and Risk Management Advisory Committee [DSaRM]) to consider the cardiovascular safety of febuxostat (Uloric) based on the 2018 “Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES) study. 

The Vote

Only One-Third of Gout Patients Receive Urate-Lowering Drugs

The most recent analysis of National Health and Nutrition Examination Survey [NHANES] 2007-2016) data shows the prevalence of gout to be 9.3 million in the USA.

Data from 5,467 participants from NHANES 2015-2016, finds gout in 3.9% or  9.2 million US adults.  This includes 5.2% [5.9 million] of men and 2.7% [3.3 million] of  women with gout.

Sleep Apnea Increases Gout Risk

Both Gout and obstructive sleep apnea (OSA) comingle with a wide range of serious comorbidities. A matched retrospective cohort study from the UK Clinical Practice Research database shows those with OSA are at a higher risk of developing gout.

This report compared 15,879 patients with OSA versus 63,296 without; median follow‐up was 5.8 years.

Hepatic Safety of Urate Lowering Therapies in Gout

Lee and a group of Korean investigators have analyzed the comparative safety of allopurinol and febuxostat in a small cohort of gout patients with fatty liver disease (FLD) and found febuxostat had a lower risk for hepatotoxicity (defined as AST or ALT at least 3× the upper limit of normal) compared to allopurinol.